US Patent

US8563608 — Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Method of Use · Assigned to Amarin Pharmaceuticals Ireland Ltd · Expires 2030-04-29 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for lowering triglyceride levels in subjects taking statins with triglyceride levels between 500 and 1500 mg/dl.

USPTO Abstract

The present invention relates to methods of reducing triglyceride levels in statin-treated subjects having a triglyceride level of 500 mg/dl to 1500 mg/dl.

Drugs covered by this patent

Vascepa (ICOSAPENT ETHYL) · Amarin Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1287`	—	Vascepa
`U-1287`	—	Vascepa

Patent Metadata

Patent number: US8563608
Jurisdiction: US
Classification: Method of Use
Expires: 2030-04-29
Drug substance claim: No
Drug product claim: No
Assignee: Amarin Pharmaceuticals Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.